Palatin Technologies Inc. (PTN)

Palatin Technologies, Inc. (AMEX:PTN) Q3 2024 Earnings Call Transcript - Insider Monkey

Insider Monkey

Should You Buy Palatin Technologies (PTN) Ahead of Earnings? - Yahoo News UK

Yahoo News UK

Should You Buy Palatin Technologies (PTN) Ahead of Earnings? - Yahoo News UK

Yahoo News UK

Earnings call: Palatin Technologies reports Q3 results, plans new trials - Investing.com

Investing.com

The Potential Rise in the Price of Palatin Technologies Inc. (PTN) following insiders activity – Knox Daily - Knox Daily

Knox Daily

Palatin Technologies Q3 24 Earnings Conference Call At 11:00 AM ET - Nasdaq

Nasdaq

Palatin Technologies Inc. Q3 Loss Decreases - Nasdaq

Nasdaq

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PR Newswire

PR Newswire

Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year? - Yahoo News UK

Yahoo News UK

Palatin Technologies (NYSEAMERICAN:PTN) Earns “Buy” Rating from HC Wainwright - Defense World

Defense World

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 - BioSpace

BioSpace

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 - InvestorsObserver

InvestorsObserver

Can You Imagine How Palatin Technologies's (NYSEMKT:PTN) Shareholders Feel About The 80% Share Price ... - Yahoo Movies UK

Yahoo Movies UK

Female Hypoactive Sexual Desire Disorder Therapeutics Market [2024] | Emotional Brain BV, GlaxoSmithKline Plc ... - Motions Online

Motions Online

FDA clears Palatin's obesity treatment for Phase 2 trial - Investing.com

Investing.com

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP ... - PR Newswire

PR Newswire

Palatin stock gains as FDA OKs obesity trial (NYSE:PTN) - Seeking Alpha

Seeking Alpha

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in ... - Financial Times

Financial Times

Palatin to Host Virtual KOL Event “Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in ... - The Malaysian Reserve

The Malaysian Reserve

Female Hypoactive Sexual Desire Disorder Therapeutics Market 2024–2032 Global Competition, New Growth ... - WBLZMedia

WBLZMedia

PTN's latest rating updates from top analysts. – Knox Daily - Knox Daily

Knox Daily

Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying

Benzinga

Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying By Benzinga - Investing.com UK

Investing.com UK

Palatin Technologies director buys $12.7k in stock - Investing.com India

Investing.com India

Palatin Technologies director buys $12.7k in stock By Investing.com - Investing.com Nigeria

Investing.com Nigeria

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

Zacks Investment Research

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study - Yahoo Finance

Yahoo Finance

Palatin's dry eye treatment shows promise in Phase 3 trial - Investing.com

Investing.com

Palatin Technologies, Inc. (PTN) Stock Is Lower By -21.63% This Week: Buy, Hold, or Sell? - InvestorsObserver

InvestorsObserver

Palatin to push through with dry eye therapy despite Phase III miss - Clinical Trials Arena

Clinical Trials Arena

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Dow Dips 200 Points; TJX Posts Upbeat Sales

Benzinga

Palatin Technologies Shares Tumble Premarket on Dry-Eye Study Results - MarketWatch

MarketWatch

Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript - Yahoo Finance

Yahoo Finance

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PR Newswire

PR Newswire

PTN Stock Quote Price and Forecast - CNN

CNN

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye ... - PR Newswire

PR Newswire

Palatin Technologies Announces Offering Closure and Vyleesi Sale - TipRanks.com - TipRanks

TipRanks

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Zacks Investment Research

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength? - Yahoo Finance

Yahoo Finance

3 Penny Stocks to Buy to Unlock 2500% Upside Potential - InvestorPlace

InvestorPlace

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 - Yahoo Finance

Yahoo Finance

Cosette Pharmaceutical Acquires Vyleesi - FinSMEs

FinSMEs

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. - Yahoo Finance

Yahoo Finance

Analysts Say 3 Stocks Have a Combined Upside of 3000% - Yahoo Finance

Yahoo Finance

Analysts Say 3 Stocks Have a Combined Upside of 3000% - InvestorPlace

InvestorPlace

Cosette buys female libido drug Vyleesi from divesting Palatin - FiercePharma

FiercePharma

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American - PR Newswire

PR Newswire

Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket

Benzinga

Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - PR Newswire

PR Newswire